Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Gastroenterology. 2019 Nov 9;158(3):679–692.e1. doi: 10.1053/j.gastro.2019.10.038

Figure 2. ZIP4 enhances pancreatic cancer growth and gemcitabine resistance through integrin α3β1.

Figure 2.

(A). Expression of ITGA3 and ITGB1 in MIA PaCa-2 and AsPC-1 cells. (B). IHC staining of ITGA3 and ITGB1 in pancreatic cancer specimens and adjacent benign tissues. Quantified data are plotted on right. (C). Tumor weight. Representative xenograft pictures were shown (n=5). (D). Cell viability following gemcitabine treatment for 2 days. (E). Spheroid growth assay. Spheroid growth was assessed in MIA-ZIP4 siITGA3, MIA-ZIP4 siITGB1 cells at 48 h post gemcitabine treatment. The scale bar is 200 μm. (F). Stable cells were orthotopically implanted (n=5/group). All the mice were administrated with gemcitabine. Representative tumors were shown. Tumors in MIA-V shV group were circled in dotted white since the tumors were too small.